Zhonghua Yu Fang Yi Xue Za Zhi. 2026 Sep 6;60(9):1405-1416. doi: 10.3760/cma.j.cn112150-20260115-00045.
ABSTRACT
Pollen-induced allergic rhinitis is a common respiratory allergic disease that significantly impairs patients’ quality of life. Available evidence indicates that preventive treatment initiated before the pollen season can effectively alleviate in-season symptoms and delay disease onset; however, standardized and unified preventive treatment strategies are still lacking in China. This consensus was developed by a multidisciplinary panel of experts using the Delphi method. The evidence on preseasonal preventive treatment for pollen-induced allergic rhinitis was systematically reviewed, and through multiple rounds of expert discussions and anonymous voting, core recommendations were formulated. This consensus recommends that oral second-generation antihistamines be initiated 1-2 weeks before the pollen season and intranasal corticosteroids 2-4 weeks before the pollen season, with both continued until the end of the pollen season; the latter is particularly indicated for patients with moderate-to-severe allergic rhinitis. Biologics targeting type 2 inflammation have demonstrated efficacy during the pollen season, but additional evidence is required to support their use as preventive medications. Leukotriene receptor antagonists are not recommended as monotherapy for preventive treatment. In China, allergen immunotherapy is mainly administered as a continuous, year-round regimen, and short-term intermittent preseasonal use is currently not recommended. Systemic corticosteroids and decongestants are not recommended for preventive use. This consensus aims to provide a scientific and standardized basis for clinical decision-making, thereby improving symptom control and enhancing patients’ quality of life.
PMID:42736145 | DOI:10.3760/cma.j.cn112150-20260115-00045
